Crescendo Biologics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Crescendo Biologics Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Crescendo Biologics presents a practical BD-screening case because its returned pipeline contains 13 records and the deal search returned 4 transaction records. The lead returned asset is CB-307, associated with 4-1BB x PSMA x albumin and PSMA-Positive Castration-Resistant Prostatic Cancer, Bone metastases, Neoplasm Metastasis, at Phase 1. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | CB-307 | Crescendo Biologics Ltd. | Phase 1 | Pipeline record: 4-1BB x PSMA x albumin; PSMA-Positive Castration-Resistant Prostatic Cancer, Bone metastases, Neoplasm Metastasis. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Crescendo Biologics has entered into a pre-clinical collaboration agreement with Orano Med | Phase 1 asset with 4-1BB x PSMA x albumin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | CB-213 | Crescendo Biologics Ltd. | Preclinical | Pipeline record: LAG3 x PD-1; Solid tumor. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic | Preclinical asset with LAG3 x PD-1 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | 5T4 x CD137 x HSA(Crescendo Biologics) | Crescendo Biologics Ltd. | Preclinical | Pipeline record: target not returned; Prostatic Cancer. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications | Preclinical asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | 5T4xCD137xHSA(Crescendo) | Crescendo Biologics Ltd. | Preclinical | Pipeline record: 4-1BB x 5T4 x albumin; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Crescendo Biologics has entered into a pre-clinical collaboration agreement with Orano Med | Preclinical asset with 4-1BB x 5T4 x albumin exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | CB-699 | Crescendo Biologics Ltd. | Preclinical | Pipeline record: 4-1BB x CD40 x MSLN; Mesothelin positive Neoplasms, Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic | Preclinical asset with 4-1BB x CD40 x MSLN exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2020-07-07 | Crescendo Biologics has entered into a pre-clinical collaboration agreement with Orano Med | Active | disclosed: false |
| 2020-05-05 | Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic | Active | disclosed: false |
| 2018-05-30 | Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications | Active | disclosed: false |
The most relevant returned precedent is: Crescendo Biologics has entered into a pre-clinical collaboration agreement with Orano Med (2020-07-07). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- iBio, Inc. - 2024 Quarterly report: iBio, Inc. - 2024 Quarterly report We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position. We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. In an effort to improve liquidity and our runway, we have consummated the sale of our Facility, reduced our work force, signed a collaboration with AstralBio with to discover and develop novel antibodies for obesity and other cardiometabolic diseases, entered into a securities purchase agreement for a PIPE financing resulting in gross proceeds of approximately $15.0 million. Potential options being considered to further increase liquidity, focusing product development on a select number
- Chiome Bioscience Inc. - Annual securities report-17th Period(2020.01.01-2020.12.31): Chiome Bioscience Inc. - Annual securities report-17th Period(2020.01.01-2020.12.31) b.资本の财源及び资金の流动性についての分析 当社は研究开発型ベンチャー企业であり、研究开発のための先行投资が必要となっております。资本の财源と なる収益については、これまで主として提携先制薬企业等から委受托业务による収益を获得しており、加えて、 保有する创薬パイプラインの导出により契约一时金、マイルストーン収入等を计上しております。将来におい て、当社が保有する创薬パイプラインが新たに导出に至った场合には、契约一时金、マイルストーン収入の増加 が见込まれ、また、医薬品が上市された场合には贩売ロイヤルティを受领することとなります。导出に至るまで の先行投资期间においては研究开発费の支出等から営业活动によるキャッシュ・フローはマイナスを计上する计 画であり、当事业年度においては、CBA-1205の临床开発やCBA-1535のCMC开発の进展などによる前渡金等の支払 が発生したことにより、営业活动によるキャッシュ・フローは1,360,143千円の支出となりました。 なお、上记先行投资期间における営业活动によるキャッシュ・フローのマイナスについて、现在既に収益を得 ている创薬支援事业における１社ごとの取引量や新たに取引先を拡大することで営业キャッシュ・フローの改善 に努めております。また、财务活动によるキャッシュ・フローについては、助成金の获得や必要に応じた资金调 达等により补填を行っております。资金调达においては、新株予约権の発行によるエクイティファイナンスに加 え、有利子负债の调达も含めて実施しており、调达上の安定性の确保の観点や财务レバレッジにも留意しており ます。
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Crescendo Biologics is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Crescendo Biologics merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate CB-307, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
